CA2910398A1 - Methods, systems, and compositions for promoting bone growth - Google Patents

Methods, systems, and compositions for promoting bone growth

Info

Publication number
CA2910398A1
CA2910398A1 CA2910398A CA2910398A CA2910398A1 CA 2910398 A1 CA2910398 A1 CA 2910398A1 CA 2910398 A CA2910398 A CA 2910398A CA 2910398 A CA2910398 A CA 2910398A CA 2910398 A1 CA2910398 A1 CA 2910398A1
Authority
CA
Canada
Prior art keywords
oxopyrrolidin
hydroxy
methyl
difluoro
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2910398A
Other languages
English (en)
French (fr)
Inventor
Stephen Douglas Barrett
Joseph Michael Colombo
Bradlee David Germain
Andriy Kornilov
James Bemard Kramer
Adam Uzieblo
Gregory William Endres
Fred Lawrence Ciske
Thomas Allen Owen
James Paul O'malley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MYOMETRICS LLC
Cayman Chemical Co Inc
Original Assignee
MYOMETRICS LLC
Cayman Chemical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MYOMETRICS LLC, Cayman Chemical Co Inc filed Critical MYOMETRICS LLC
Publication of CA2910398A1 publication Critical patent/CA2910398A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3608Bone, e.g. demineralised bone matrix [DBM], bone powder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24Collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645Connective tissue
    • A61L27/365Bones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/42Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
    • A61L27/425Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/02Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
CA2910398A 2013-07-19 2014-07-18 Methods, systems, and compositions for promoting bone growth Abandoned CA2910398A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361856370P 2013-07-19 2013-07-19
US61/856,370 2013-07-19
US201461928843P 2014-01-17 2014-01-17
US61/928,843 2014-01-17
PCT/US2014/047138 WO2015009991A2 (en) 2013-07-19 2014-07-18 Methods, systems, and compositions for promoting bone growth

Publications (1)

Publication Number Publication Date
CA2910398A1 true CA2910398A1 (en) 2015-01-22

Family

ID=51352759

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2910398A Abandoned CA2910398A1 (en) 2013-07-19 2014-07-18 Methods, systems, and compositions for promoting bone growth

Country Status (9)

Country Link
US (1) US10729810B2 (https=)
EP (1) EP3021879A2 (https=)
JP (1) JP2016527006A (https=)
KR (1) KR20160048054A (https=)
CN (1) CN105392505A (https=)
AU (1) AU2014290512A1 (https=)
CA (1) CA2910398A1 (https=)
PH (1) PH12015502854A1 (https=)
WO (1) WO2015009991A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107802623B (zh) 2012-07-19 2020-10-30 开曼化学股份有限公司 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物
US20170128172A1 (en) * 2014-06-20 2017-05-11 3-D Matrix, Ltd. Materials and methods for filling dental bone voids
US9657052B2 (en) 2014-12-09 2017-05-23 Warsaw Orthopedic, Inc. Compounds and methods of making sterols using diols
CN105012995B (zh) 2015-06-04 2018-03-09 武汉维斯第医用科技股份有限公司 一种含促骨愈合药物的胶原蛋白海绵及其制备方法
WO2016196925A1 (en) * 2015-06-04 2016-12-08 The Regents Of The University Of California Composition for bone and methods of making and using the same
US9987289B2 (en) 2015-07-10 2018-06-05 Warsaw Orthopedic, Inc. Slow release oxysterols and methods of use
US9878070B2 (en) 2015-06-17 2018-01-30 Warsaw Orthopedic, Inc. Malleable implants including an oxysterol and methods of use
US10632230B2 (en) 2015-07-10 2020-04-28 Warsaw Orthopedic, Inc. Implants having a high drug load of an oxysterol and methods of use
US9877836B2 (en) 2015-07-10 2018-01-30 Warsaw Orthopedic, Inc. Compression resistant implants including an oxysterol and methods of use
US12171909B2 (en) 2015-07-10 2024-12-24 Warsaw Orthopedic, Inc. Implants having a drug load of an oxysterol and methods of use
HU231033B1 (hu) 2016-03-22 2019-12-30 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Eljárás 3-as kötést tartalmazó optikailag aktív karbonsavak, karbonsav sók és karbonsav származékok előállítására
CN105816919B (zh) * 2016-05-23 2019-06-11 烟台正海生物科技股份有限公司 一种含有天然纳米羟基磷灰石的复合材料及其制备方法
EP3526242A1 (en) 2016-10-12 2019-08-21 University of Copenhagen Peptide dual agonists of gipr and glp2r
US11384114B2 (en) 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
CN106699604B (zh) * 2017-01-09 2019-01-01 四川同晟生物医药有限公司 一种沙库比曲及其中间体的制备方法
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
CN108822090B (zh) * 2018-08-17 2020-11-17 杭州乐敦科技有限公司 一种他汀类药物中间体的制备方法
WO2020051646A1 (en) * 2018-09-14 2020-03-19 Orthocell Limited Artificial periosteum
WO2020140054A1 (en) 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20220133957A1 (en) * 2019-02-04 2022-05-05 Emory University Sclerostin Inhibitors That Promote Bone Morphogenetic Protein Expression
CN110590351B (zh) * 2019-08-23 2021-05-25 中国科学院上海硅酸盐研究所 一种黑色生物活性陶瓷粉体及其应用
CN114014647B (zh) * 2021-10-21 2022-12-16 华南理工大学 一种硅酸锌复合磷酸三钙陶瓷支架及其制备方法与应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
DE2517771A1 (de) 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
CA1085859A (en) 1975-06-27 1980-09-16 Wilhelm Bartmann Pyrrolidones and process for their manufacture
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4268522A (en) 1976-06-14 1981-05-19 Pfizer Inc. 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
US7229959B1 (en) 1990-11-27 2007-06-12 The American National Red Cross Supplemented fibrin matrix delivery systems
CA2093836A1 (en) 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
JP3388867B2 (ja) 1994-03-31 2003-03-24 株式会社東芝 宛名領域検出装置および宛名領域検出方法
AU1120295A (en) 1994-11-07 1996-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cartilage-derived morphogenetic proteins
US7517539B1 (en) 1996-10-16 2009-04-14 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
ZA984040B (en) 1997-05-15 1998-11-20 Ono Pharmaceutical Co Benzenesulfonamide compounds
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
AP2001002357A0 (en) 1999-12-22 2001-12-31 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis.
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
WO2002024647A1 (en) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
PT1339678E (pt) * 2000-11-27 2007-11-30 Pfizer Prod Inc Agonistas selectivos do receptor ep4 no tratamento de osteoporose
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
ES2254726T3 (es) 2001-07-16 2006-06-16 F. Hoffmann-La Roche Ag Analogos de prostaglandina como agonistas receptores de ep4.
RU2296122C2 (ru) 2001-07-16 2007-03-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пирролидона в качестве простаноидных агонистов и фармацевтическая композиция
NZ530885A (en) * 2001-07-23 2007-09-28 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having EP4 agonist as the active ingredient
JP4550417B2 (ja) 2001-10-23 2010-09-22 メルク セローノ ソシエテ アノニム プロスタグランジンep2及び/又はep4受容体のリガンドとしてのポリアゾリジノン化合物
US20040204590A1 (en) 2001-12-03 2004-10-14 Ogidigben Miller J. Ep4 receptor agonist, compositions and methods thereof
CA2466757A1 (en) 2001-12-03 2003-06-12 Merck & Co., Inc. Method for treating ocular hypertension
AU2003211574A1 (en) 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
CA2478653A1 (en) 2002-03-18 2003-09-25 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
BR0308493A (pt) 2002-03-18 2005-01-11 Pfizer Prod Inc Uso de agonistas de receptor seletivo de ep4 para o tratamento da insuficiência hepática, perda de permeabilidade do canal arterial, glaucoma ou hipertensão ocular
US7326426B2 (en) 2002-03-29 2008-02-05 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable liquid polymers
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7419999B2 (en) 2002-06-10 2008-09-02 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
AU2003275840A1 (en) 2002-10-25 2004-05-13 Merck Frosst Canada Ltd 2-pyrrolidones as EP4 receptor agonists
US7256211B1 (en) 2003-01-21 2007-08-14 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medical use thereof
ATE394372T1 (de) 2003-03-03 2008-05-15 Serono Lab G-lactamderivate als prostaglandinagonisten
US7163920B2 (en) 2003-09-30 2007-01-16 Ethicon, Inc. Peptide with osteogenic activity
US20070191319A1 (en) 2003-12-17 2007-08-16 Pfizer Inc. Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US20080234337A1 (en) 2004-08-10 2008-09-25 Ono Pharmaceutical Co., Ltd. Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist
EP1782830A4 (en) 2004-08-10 2009-07-29 Ono Pharmaceutical Co PREVENTION AND / OR REMEDY FOR LOWER URINARY TRACT DISEASES CONTAINING AN EP4 AGONIST
US20060039949A1 (en) 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060057184A1 (en) 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
US7621963B2 (en) * 2005-04-13 2009-11-24 Ebi, Llc Composite bone graft material
BRPI0610469A2 (pt) 2005-05-27 2012-10-23 Royer Biomedical Inc composição bioerodìvel para a administração de um agente bioativo, kit para a formação de uma composição bioerodìvel, métodos de produção de uma composição bioerodìvel solidificada para a administração de um agente bioativo, de produção de uma fibra bioerodìvel para a administração de um agente bioativo e de formação de um filme bioerodìvel para a administração de um agente bioativo, dispositivo médico implantável, e, método de administração de um agente bioativo para um local do corpo necessitando do mesmo
CN103349793B (zh) 2005-09-09 2016-02-10 阿格诺沃斯健康关爱公司 复合骨移植替代物水泥以及由其制得的制品
KR20060013354A (ko) 2005-12-09 2006-02-09 (주)코리아 본 뱅크 인산칼슘계 시멘트 첨가에 의해 개질된 탈회골 기질의 개발
US20070232660A1 (en) 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
KR20100086485A (ko) 2007-10-23 2010-07-30 알러간, 인코포레이티드 치료적 치환된 락탐
US20090112332A1 (en) 2007-10-31 2009-04-30 Alexis Paul Shelokov Bone graft and bone graft substitutes with antibiotics for sustained, localized release of antibiotics for reducing postoperative surgical wound infection in spinal and other bone surgery
WO2011127149A1 (en) 2010-04-06 2011-10-13 University Of Utah Research Foundation Controlled release combination biomaterials
US8685432B2 (en) 2008-03-25 2014-04-01 University Of Utah Research Foundation Controlled release tissue graft combination biomaterials
WO2009129316A2 (en) * 2008-04-15 2009-10-22 Etex Corporation Minimally invasive treatment of vertebra (mitv) using a calcium phosphate combination bone cement
WO2010011599A2 (en) 2008-07-22 2010-01-28 Osteogenex Inc. Pimethixene derivatives for promoting bone growth
WO2010025135A2 (en) 2008-08-28 2010-03-04 Osteogenex Inc. Trimeprazine and ethopropazine derivatives for promoting bone growth
DE102008047405A1 (de) * 2008-09-11 2010-04-15 Technische Universität Dresden Kompositmaterialien aus einer mit Silikat und Calciumphosphatphasen mineralisierten Kollagenmatrix, Verfahren zu deren Herstellung und deren Verwendung
JP2010273847A (ja) * 2009-05-28 2010-12-09 Tokyo Institute Of Technology 高密度多孔質複合体
US20120270934A1 (en) 2009-07-03 2012-10-25 Concert Pharmaceuticals, Inc. Prostacyclin derivatives
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
CA2815179A1 (en) 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
US8613938B2 (en) * 2010-11-15 2013-12-24 Zimmer Orthobiologics, Inc. Bone void fillers
US20120283293A1 (en) 2011-05-06 2012-11-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation
JP6052175B2 (ja) 2011-08-02 2016-12-27 小野薬品工業株式会社 左室拡張機能改善剤
CN107802623B (zh) 2012-07-19 2020-10-30 开曼化学股份有限公司 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
EP3235817B1 (en) 2013-03-15 2018-12-12 Cayman Chemical Company, Incorporated Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions

Also Published As

Publication number Publication date
US10729810B2 (en) 2020-08-04
WO2015009991A2 (en) 2015-01-22
WO2015009991A3 (en) 2015-07-16
AU2014290512A8 (en) 2016-06-16
AU2014290512A1 (en) 2015-11-12
KR20160048054A (ko) 2016-05-03
US20160158413A1 (en) 2016-06-09
WO2015009991A8 (en) 2015-12-17
CN105392505A (zh) 2016-03-09
EP3021879A2 (en) 2016-05-25
PH12015502854A1 (en) 2016-03-28
JP2016527006A (ja) 2016-09-08

Similar Documents

Publication Publication Date Title
CA2910398A1 (en) Methods, systems, and compositions for promoting bone growth
AU2017200044B2 (en) Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated disease and conditions
AU2014228973B2 (en) Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
WO2014144610A1 (en) Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
HK1239518B (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
HK1239518A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
HK1205937B (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
HK1237785A1 (en) Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
HK1206016B (en) Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151023

FZDE Discontinued

Effective date: 20190219